Translational research in drug development: challenges and opportunities for pharmacists
TL;DR
It is posits that a paradigm shift toward Open Science frameworks, systems pharmacology, and precision individualization is imperative for overcoming the epistemological opacity of modern drug discovery and achieving global therapeutic equity.
Abstract
Translational Research (TR) constitutes a multidirectional, iterative paradigm designed to facilitate the seamless transition of fundamental biomolecular discoveries into robust clinical interventions. The review critically examines the five - tier (T0 - T4) t ranslational trajectory, identifying the systemic biological and operational bottlenecks - most notably the “Valley of Death” and xenogeneic discordance - that perpetuate the high rates of therapeutic attrition within the pharmaceutical pipeline. Furthermore , it delineates the emergence of the pharmacist as a translational catalyst, uniquely equipped to bridge the gap between abstract molecular hypotheses and patient - centric outcomes through the application of pharmacometrics, Physiologically Based Pharmacoki netic (PBPK) modelling, and Model - Informed Drug Development (MIDD). By integrating multi - modal “omics” data with real - world evidence (RWE), the modern pharmacist optimizes the therapeutic index and ensures the clinical scalability of novel chemical entitie s. This paper posits that a paradigm shift toward Open Science frameworks, systems pharmacology, and precision individualization is imperative for overcoming the epistemological opacity of modern drug discovery and achieving global therapeutic equity.